Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 81

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 81
---
 ● | 154 shares of our common stock issuable upon the exercise of the Class A 
 Common Stock Warrants, with an exercise price of $55,272.00 per share;   |

| ● | 497 shares of our common stock issuable upon the exercise                             
 of the Class B Common Stock Warrants, with an exercise price of $10,080.00 per share; |

| ● | 35 shares of our common stock issuable upon the exercise                                 
 of the Class B Placement Agent Warrants, with an exercise price of $12,600.00 per share; |

| ● | 194 shares of our common stock issuable upon the alternative                                                                        
 cashless exercise of the Class C Common Stock Warrants, or 485 shares of our common stock upon cash exercise with an exercise price 
 of $16.00 per share;                                                                                                                |

| ● | 5,060 shares of common stock issuable upon the exercise of                    
 the Class D Common Stock Warrants, with an exercise price of $3.76 per share; |

| ● | 64,506 shares of common stock issuable upon the exercise of the Class E Common Stock Warrants, with an exercise price of $16.00 per share; |

| ● | 125,000 shares of our common stock issuable upon the alternative cashless exercise of the Class F Common Stock Warrants, or 62,500 shares of our common stock upon cash exercise with an exercise price of $16.00 per share; |

| ● | 1,621,463 shares of common stock issuable upon the exercise of the Class G Common Stock Warrants, with an exercise price of $3.76 per share; and |

| ● | shares of common stock issuable upon the exercise of the Class H-1 Warrants 
 and Class H-2 Warrants issued pursuant to this offering.                    |

47 MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the notes included elsewhere in this prospectus. The following discussion contains forward-looking statements that involve certain risks and uncertainties. Our actual results could differ materially from those discussed in these statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement/prospectus, particularly under the “Risk Factors” and “Disclosure Regarding Forward-Looking Statements” sections. Throughout this section, unless otherwise noted